Comment from Dentons Bingham Greenebaum LLP, submitting on behalf of a client, who is a state-licensed 503A compounding pharmacy
AnonymousSupportBusiness
Summary: A state-licensed 503A compounding pharmacy is submitting a nomination for the bulk drug substance TB-500. They argue that TB-500 is a promising therapeutic peptide for regenerative medicine and tissue repair, citing various preclinical and clinical studies that demonstrate its safety and efficacy in wound healing, cardiovascular, and neurological contexts.
The attached materials are being submitted on behalf of a state-licensed 503A compounding pharmacy. The materials were prepared by a licensed pharmacist in consultation with other licensed medical professionals and are being submitted as a public comment in support of the proposed nomination. The materials are not intended to constitute legal advice and were neither prepared by nor express the opinions of Dentons Bingham Greenebaum LLP.